IL-6 Shows Promise as Early Sepsis ​biomarker ⁣in High-Risk groups

A recent⁢ study suggests that interleukin-6 (IL-6) could be ⁤a ⁣valuable diagnostic tool for the early detection of​ sepsis, notably in vulnerable populations such as newborns, children, and pregnant women.The research, presented at the ⁤Global 2025 Escmid conference, marks the first comprehensive evaluation of‌ IL-6’s diagnostic performance across all three of these high-risk groups.

Sepsis, a life-threatening condition arising from the body’s overwhelming⁣ response to an infection, remains a major global health ⁣challenge. The condition‍ is responsible for an estimated 11 million deaths each year.

Young children, especially those under the⁢ age of five, and pregnant women face a heightened risk​ of sepsis due to immunological changes‍ and increased susceptibility to infections.Diagnosing sepsis in pregnant women presents unique challenges,⁣ as normal physiological ​changes ⁣during pregnancy can obscure early warning signs of the disease.

The ⁣Need for Early Detection

Early and accurate diagnosis is critical for improving outcomes in sepsis cases. ⁤However, the ​non-specific nature of sepsis symptoms and ‍the limitations of traditional biomarkers, such as C-reactive protein (CRP) and procalcitonin ​(PCT), which exhibit delayed responses and suboptimal sensitivity, complicate early detection efforts.

Given the rapid progression of ‌sepsis, medical professionals are actively seeking‍ biomarkers that can enable faster,‌ more​ precise diagnoses and facilitate timely, effective treatment interventions.

Study Details

The retrospective study, published in the⁢ European Medical Journal – EMJ, analyzed blood samples ‍collected ⁢at regular intervals from 252 patients suspected of⁢ having sepsis. The ⁤study cohort included 111 pediatric patients,72‌ pregnant women,and 69 newborns.

Researchers classified patients ‌based⁢ on the type of infection (bacterial, viral, ⁢or absence of infection) and​ their physiological response‌ (normal, systemic inflammatory response syndrome, sepsis, or septic shock). Diagnostic accuracy was assessed using⁢ the area under the receiver operating characteristic (AUROC) curve, where ‌a score of ⁣1.0 indicates a perfect ​test and 0.5 indicates a completely ineffective test.

IL-6 Performance

The study found that IL-6 consistently outperformed traditional biomarkers in differentiating bacterial infections from‍ non-bacterial infections.IL-6 achieved AUROC scores of 0.91 0.94 in pregnant patients, and 0.86 in newborns. The biomarker also proved effective in assessing sepsis severity, successfully ​distinguishing between mild infections, sepsis, and septic shock – a crucial capability for tailoring treatment strategies.

In⁤ terms of sensitivity and specificity, IL-6 exceeded 80% in pediatric and pregnant ​patients, detecting bacterial infections with a sensitivity of 91% in children and 94% ‍in pregnant women. While IL-6 maintained high specificity (97.1%) in newborns, ⁤its sensitivity‌ was​ lower (67.6%).

the study authors ⁤suggest that the lower sensitivity and‍ AUROC values observed in newborns may be partially attributed to ​the inherent complexity⁣ of diagnosing neonatal sepsis, for which a universally accepted standard definition is lacking. The wide range‌ of clinical manifestations associated with neonatal‌ sepsis may ‍also contribute to these differences.

Advantages of IL-6

Dr. Seán ⁤Whelan, the lead author of the study, highlighted the advantages of IL-6 over traditional biomarkers. “The secretion of IL-6 increases in one to ​two hours, reaches a peak at six hours, and drops in 24 hours, while CRP and PCT reach⁢ their peaks⁣ much later, at⁤ 48 and 24 hours, respectively,”⁢ Dr. whelan said. “This offers​ a key advantage over existing markers for the early identification of sepsis.”

Dr. Whelan also noted the increasing clinical use ​of‍ IL-6 testing. “In ⁤our institutions – Round Hospital and Children’s Health Ireland –​ IL-6 is already used for these categories⁣ of patients,” he stated.

The increased adoption of IL-6 ⁢testing has been facilitated by the availability⁢ of commercial assays compatible with⁢ widely used laboratory platforms, providing ‍real-time results. The COVID-19 pandemic further accelerated this trend,⁤ with IL-6 testing becoming more common for evaluating‌ inflammation ⁣in patients.

Dr. Whelan⁢ concluded that ‍the study results support⁣ the potential of IL-6 as an meaningful biomarker in the diagnosis​ of sepsis.

The authors believe that widespread use of IL-6,⁣ in conjunction with clinical evaluation, could substantially improve medical decision-making and the initiation of personalized treatments in high-risk patients.